Global Tissue Engineering Market Size & Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tissue engineering market will help companies and investors design strategic landscapes.

orthopedics,musculoskeletal, & spine was the largest segment with a revenue share of 59.53% in 2023. Horizon Databook has segmented the Global tissue engineering market based on cord blood & cell banking, cancer, gi, gynecology, dental, skin & integumentary, urology, orthopedics,musculoskeletal, & spine, neurology, cardiology & vascular covering the revenue growth of each sub-segment from 2018 to 2030.

Stem cell therapies have significant potential as therapeutics across various clinical applications. This has resulted in substantial global investments in research and clinical translation. Rapid advances in stem cell research aid in improved disease management. Thus, with an increase in the incidence of cancer, diabetes, and other chronic disorders, research on stem cells has increased.

In May 2023, European Pharmaceutical Review (EPR) released an article where it examines how technological advancements are revolutionizing ATMP manufacturing as well as current advances in stem cell therapy for a number of difficult-to-treat diseases or disorders. The first female patient with HIV who was of mixed racial background was demonstrated to enter remission using stem cells from cord blood in study findings reported in March 2023.

According to the researchers, using stem cells from cord blood rather than suitable adult donors has been done in the past and it boosts the possibility of curing HIV with stem cell transplantation in persons of all racial origins. Mesenchymal precursor cells (MPCs) have been shown to be effective at reducing inflammation in the largest cell therapy study for chronic heart failure caused by low ejection fraction (EF) that has been conducted to date in February 2023.